C. Lee and I. Tannock, The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors, BMC Cancer, vol.14, issue.7, p.255, 2010.
DOI : 10.1158/1078-0432.CCR-07-4465

W. De-roock, D. Vriendt, V. Normanno, N. Ciardiello, F. et al., KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer, The Lancet Oncology, vol.12, issue.6, pp.594-603, 2011.
DOI : 10.1016/S1470-2045(10)70209-6

J. Baselga, Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck, Journal of Clinical Oncology, vol.23, issue.24
DOI : 10.1200/JCO.2005.07.119

J. Vermorken, Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy, Journal of Clinical Oncology, vol.25, issue.16, pp.2171-2177, 2007.
DOI : 10.1200/JCO.2006.06.7447

L. Liu, Y. Cao, A. Tan, C. Liao, and F. Gao, Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials, Cancer Chemotherapy and Pharmacology, vol.9, issue.3, pp.849-861, 2010.
DOI : 10.1007/s00280-009-1090-x

X. Li, Y. Lu, K. Liang, T. Pan, J. Mendelsohn et al., Requirement of hypoxia-inducible factor-1?? down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab, Molecular Cancer Therapeutics, vol.7, issue.5, pp.1207-1217, 2008.
DOI : 10.1158/1535-7163.MCT-07-2187

S. Huang, J. Li, and P. Harari, Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade, Mol Cancer Ther, vol.1, issue.7, pp.507-514, 2002.

R. Clynes, T. Towers, L. Presta, and J. Ravetch, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat Med, vol.6, issue.4, pp.443-446, 2000.

J. Kurai, Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines, Clinical Cancer Research, vol.13, issue.5, pp.1552-1561, 2007.
DOI : 10.1158/1078-0432.CCR-06-1726

P. Steiner, Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor, Clinical Cancer Research, vol.13, issue.5, pp.1540-1551, 2007.
DOI : 10.1158/1078-0432.CCR-06-1887

D. Raben, The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer, Clin Cancer Res, vol.11, issue.2, pp.795-805, 2005.

N. Wilson, An Fc?? Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in??Cancer Cells, Cancer Cell, vol.19, issue.1, pp.101-113, 2011.
DOI : 10.1016/j.ccr.2010.11.012

R. Marechal, Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients, BMC Cancer, vol.10, issue.1, p.340, 2010.
DOI : 10.1158/1078-0432.CCR-04-0225

A. Lopez-albaitero, Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells, Cancer Immunology, Immunotherapy, vol.10, issue.11, pp.1853-1864, 2009.
DOI : 10.1007/s00262-009-0697-4

F. Bibeau, Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan, Journal of Clinical Oncology, vol.27, issue.7, pp.1122-1129, 2009.
DOI : 10.1200/JCO.2008.18.0463

R. Ferris, E. Jaffee, and S. Ferrone, Tumor Antigen???Targeted, Monoclonal Antibody???Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape, Journal of Clinical Oncology, vol.28, issue.28, pp.4390-4399, 2010.
DOI : 10.1200/JCO.2009.27.6360

L. Qiu, Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies, European Journal of Cancer, vol.46, issue.15, pp.2781-2787, 2010.
DOI : 10.1016/j.ejca.2010.05.022

J. Rodriguez, Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer, European Journal of Cancer, vol.48, issue.12, pp.1774-1780, 2012.
DOI : 10.1016/j.ejca.2012.01.007

S. Lee, R. Srivastava, A. Lopez-albaitero, S. Ferrone, and R. Ferris, Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity, Immunologic Research, vol.185, issue.11, pp.2-3248, 2011.
DOI : 10.1007/s12026-011-8231-0

W. Lin, Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies, Blood, vol.112, issue.3, pp.699-707, 2008.
DOI : 10.1182/blood-2007-11-122465

X. Yang, X. Zhang, E. Mortenson, O. Radkevich-brown, Y. Wang et al., Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses, Molecular Therapy, vol.21, issue.1, pp.91-100, 2013.
DOI : 10.1038/mt.2012.184

P. Schuler, EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma, Journal of Translational Medicine, vol.9, issue.1, p.168, 2011.
DOI : 10.1016/j.oraloncology.2009.03.006

R. Srivastava, Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients, Clinical Cancer Research, vol.19, issue.7, pp.1858-1872, 2013.
DOI : 10.1158/1078-0432.CCR-12-2426

J. Mendelsohn and J. Baselga, Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer, Journal of Clinical Oncology, vol.21, issue.14, pp.2787-2799, 2003.
DOI : 10.1200/JCO.2003.01.504

O. Dassonville, Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer., Journal of Clinical Oncology, vol.11, issue.10, pp.1873-1878, 1993.
DOI : 10.1200/JCO.1993.11.10.1873

H. Kohrt, CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies, Blood, vol.117, issue.8, pp.2423-2432, 2011.
DOI : 10.1182/blood-2010-08-301945
URL : https://hal.archives-ouvertes.fr/hal-00743985

H. Kohrt, Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer, Journal of Clinical Investigation, vol.122, issue.3, pp.1066-1075, 2012.
DOI : 10.1172/JCI61226DS1
URL : https://hal.archives-ouvertes.fr/inserm-00869052

I. Melero, S. Hervas-stubbs, G. M. Pardoll, D. Chen, and L. , Immunostimulatory monoclonal antibodies for cancer therapy, Nature Reviews Cancer, vol.10, issue.2, pp.95-106, 2007.
DOI : 10.1038/nrc2051

R. Wilcox, Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells, The Journal of Immunology, vol.168, issue.9, pp.4262-4267, 2002.
DOI : 10.4049/jimmunol.168.9.4262

H. Narazaki, Y. Zhu, L. Luo, G. Zhu, and L. Chen, CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells, Blood, vol.115, issue.10, pp.1941-1948, 2010.
DOI : 10.1182/blood-2008-12-192591

T. Baessler, CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells, Blood, vol.115, issue.15, pp.3058-3069, 2010.
DOI : 10.1182/blood-2009-06-227934

I. Melero, J. Johnston, W. Shufford, R. Mittler, and L. Chen, NK1.1 Cells Express 4-1BB (CDw137) Costimulatory Molecule and Are Required for Tumor Immunity Elicited by Anti-4-1BB Monoclonal Antibodies, Cellular Immunology, vol.190, issue.2, pp.167-172, 1998.
DOI : 10.1006/cimm.1998.1396

R. Wilcox, K. Tamada, S. Strome, and L. Chen, Signaling Through NK Cell-Associated CD137 Promotes Both Helper Function for CD8+ Cytolytic T Cells and Responsiveness to IL-2 But Not Cytolytic Activity, The Journal of Immunology, vol.169, issue.8
DOI : 10.4049/jimmunol.169.8.4230

A. Maniar, Human ???? T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement, Blood, vol.116, issue.10, pp.1726-1733, 2010.
DOI : 10.1182/blood-2009-07-234211

W. Gong, Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo, Cellular and Molecular Immunology, vol.167, issue.6, pp.477-484, 2010.
DOI : 10.1007/s12026-007-0060-9

H. Kohrt, CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies, Blood, vol.117, issue.8, pp.2423-2432, 2010.
DOI : 10.1182/blood-2010-08-301945
URL : https://hal.archives-ouvertes.fr/hal-00743985

M. Cooper, T. Fehniger, and M. Caligiuri, The biology of human natural killer-cell subsets, Trends in Immunology, vol.22, issue.11, pp.633-640, 2001.
DOI : 10.1016/S1471-4906(01)02060-9

J. Bowles and G. Weiner, CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells, Journal of Immunological Methods, vol.304, issue.1-2, pp.88-99, 2005.
DOI : 10.1016/j.jim.2005.06.018

K. Juelke, CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells, Blood, vol.116, issue.8, pp.1299-1307, 2010.
DOI : 10.1182/blood-2009-11-253286

A. Mani, A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab, Breast Cancer Research and Treatment, vol.109, issue.suppl C, pp.83-89, 2009.
DOI : 10.1007/s10549-008-0251-7

N. Acquavella, Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer, Journal of Immunotherapy, vol.31, issue.6, pp.569-576, 2008.
DOI : 10.1097/CJI.0b013e318177a4ba

W. Gluck, Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin's Lymphoma: IL-2 Mediated Natural Killer Cell Expansion Correlations with Clinical Response, Clinical Cancer Research, vol.10, issue.7, pp.2253-2264, 2004.
DOI : 10.1158/1078-0432.CCR-1087-3

S. Ansell, Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma, Blood, vol.99, issue.1, pp.67-74, 2002.
DOI : 10.1182/blood.V99.1.67

R. Houot, Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion, Blood, vol.114, issue.16, pp.3431-3438, 2009.
DOI : 10.1182/blood-2009-05-223958

H. Kohrt, CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies, Blood, vol.117, issue.8, pp.2423-2432, 2011.
DOI : 10.1182/blood-2010-08-301945
URL : https://hal.archives-ouvertes.fr/hal-00743985

E. Genovesi, C. Pettey, and J. Collins, Use of adoptive transfer and Winn assay procedures in the further analysis of antiviral acquired immunity in mice protected against Friend leukemia virus-induced disease by passive serum therapy, Cancer Res, vol.44, issue.4, pp.1489-1498, 1984.

D. Jiang and H. Schwarz, Regulation of Granulocyte and Macrophage Populations of Murine Bone Marrow Cells by G-CSF and CD137 Protein, PLoS ONE, vol.30, issue.12, p.15565, 2010.
DOI : 10.1371/journal.pone.0015565.g006

X. Zhang, CD137 Promotes Proliferation and Survival of Human B Cells, The Journal of Immunology, vol.184, issue.2, pp.787-795, 2010.
DOI : 10.4049/jimmunol.0901619

O. Murillo, In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb, European Journal of Immunology, vol.2, issue.9, pp.2424-2436, 2009.
DOI : 10.1002/eji.200838958

R. Sharma, 4-1BB Ligand as an Effective Multifunctional Immunomodulator and Antigen Delivery Vehicle for the Development of Therapeutic Cancer Vaccines, Cancer Research, vol.70, issue.10, pp.3945-3954, 2010.
DOI : 10.1158/0008-5472.CAN-09-4480

D. Piccioli, S. Sbrana, E. Melandri, and N. Valiante, Contact-dependent Stimulation and Inhibition of Dendritic Cells by Natural Killer Cells, The Journal of Experimental Medicine, vol.136, issue.3, pp.335-341, 2002.
DOI : 10.1126/science.271.5256.1723

R. Wehner, K. Dietze, M. Bachmann, and M. Schmitz, The Bidirectional Crosstalk between Human Dendritic Cells and Natural Killer Cells, Journal of Innate Immunity, vol.3, issue.3, pp.258-263, 2011.
DOI : 10.1159/000323923

V. Ollion, Tumor cell-derived Ag cross-presentation in human DC induced by NK cells: mechanisms and specialization of the BDCA-3 + DC subset . Presented at: 15th International Congress of Immunology, 2013.

F. Gerosa, B. Baldani-guerra, C. Nisii, V. Marchesini, G. Carra et al., Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells, The Journal of Experimental Medicine, vol.163, issue.3, pp.327-333, 2002.
DOI : 10.1016/0952-7915(95)80026-3

R. Mailliard, Dendritic Cells Mediate NK Cell Help for Th1 and CTL Responses: Two-Signal Requirement for the Induction of NK Cell Helper Function, The Journal of Immunology, vol.171, issue.5, pp.2366-2373, 2003.
DOI : 10.4049/jimmunol.171.5.2366

S. Agaugue, E. Marcenaro, B. Ferranti, L. Moretta, and A. Moretta, Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells, Blood, vol.112, issue.5, pp.1776-1783, 2008.
DOI : 10.1182/blood-2008-02-135871

T. Matsuo, S. Nishizuka, K. Ishida, T. Iwaya, M. Ikeda et al., Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models, BMC Research Notes, vol.4, issue.1, p.140, 2011.
DOI : 10.1038/nrm883

R. Wilcox, Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors, Journal of Clinical Investigation, vol.109, issue.5, pp.651-659, 2002.
DOI : 10.1172/JCI0214184

G. Kim, V. Donnenberg, A. Donnenberg, W. Gooding, and T. Whiteside, A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: Comparisons to a 4??h 51Cr-release assay, Journal of Immunological Methods, vol.325, issue.1-2, pp.51-66, 2007.
DOI : 10.1016/j.jim.2007.05.013

N. Kotecha, Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates, Cancer Cell, vol.14, issue.4, pp.335-343, 2008.
DOI : 10.1016/j.ccr.2008.08.014

H. Koene, M. Kleijer, J. Algra, D. Roos, V. Dem-borne et al., Fc?RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc?RIIIa, independently of the Fc?RIIIa, Blood, vol.90, issue.3, pp.1109-1114, 1997.